low severity
Observed Wegovy HD price anchor maintenance_self_pay
Observed Wegovy HD maintenance_self_pay at $399/month from Novo launch release: Wegovy HD available now nationwide.
semaglutide · GLP-1 receptor agonist
Wegovy HD 7.2 mg
Preserves the split between treatment-regimen PI results and efficacy-estimand approval language.
Live fetch
Basis split
Why are there two numbers?
Novo exposes a treatment-regimen estimand in the PI and a more favorable efficacy-estimand number in approval materials. Use the treatment-regimen anchor for label-safe comparison.
Efficacy anchors
2 anchors
Label-safe anchor
TR Est.Week 72Trial: Study 8
Adults with obesity
Why this number?
Mean body-weight change at Week 72 for WEGOVY 7.2 mg injection in Study 8 using the treatment-regimen estimand.
Dose context: 7.2 mg
Approval headline
Eff. Est.Week 72Trial: STEP UP
Adults with obesity
Why this number?
Novo approval materials present 20.7% using the efficacy estimand at 72 weeks.
Dose context: 7.2 mg
Price anchors
1 anchors
Maintenance self-pay
MaintenanceDose context: 7.2 mg
Program: Novo launch self-pay guidance
Why this number?
Launch materials indicate adults prescribed Wegovy HD can expect a price of $399/month.
Self-paying adults prescribed Wegovy HD.
Patient segment: cash_pay
Launch announcement price guidance for self-paying adults prescribed Wegovy HD.
Source ledger
3 linked
backs: Maintenance self-pay
backs: Approval headline
backs: Label-safe anchor
Timeline
Change history
low severity
Observed Wegovy HD efficacy anchor efficacy_estimand
Observed Wegovy HD efficacy_estimand efficacy anchor at 20.7% from Novo approval release: Wegovy HD 7.2 mg approved in the US.
low severity
Observed Wegovy HD efficacy anchor treatment_regimen_estimand
Observed Wegovy HD treatment_regimen_estimand efficacy anchor at 18.8% from Wegovy Prescribing Information.